Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10976389 | 0.85 | BCHE (0.49) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL3241093 | 0.84 | KMT2A (0.45) | MMP1FFAR1 | |
| SCHEMBL14378211 | 0.80 | BCHE (0.49) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL2339659 | 0.79 | KIF11 (0.51) | KEAP1NFE2L2FFAR1L3MBTL1 | |
| SCHEMBL832030 | 0.79 | KMT2A (0.55) | KEAP1NFE2L2FFAR1 | |
| SCHEMBL514550 | 0.78 | BCHE (0.50) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL378766 | 0.76 | EPHX2 (0.54) | CA2EPHX2EPHX1MRGPRX4LTA4H | |
| SCHEMBL1137128 | 0.76 | LMNA (0.47) | FFAR1 | |
| SCHEMBL14426927 | 0.76 | BCHE (0.46) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL28293656 | 0.76 | MAPT (0.51) | KEAP1NFE2L2MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| EP-1292308-B1 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1292308-A4 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6599932-B1 | Highly selective in killing tumor cells but not normal cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-07-29 | — | — | US | disclosed |
| US-20030130339-A1 | ALPHA, BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | REDDY E PREMKUMAR (US) | 2003-07-10 | — | — | US | disclosed |
| US-6541475-B2 | 2-nitrostyryl-1-(naphthylmethyl)sulfone for example | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-01 | — | — | US | disclosed |
| EP-1292308-A1 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020028818-A1 | Alpha, beta-unsaturated sulfones for treating proliferative disorders | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-07 | — | — | US | disclosed |
| WO-2001078733-A1 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | KEAP1 544/4885NFE2L2 444/4885MMP2 2648/4885 |
| US-20020028818-A1 | Alpha, beta-unsaturated sulfones for treating proliferative disorders | QSOX1, CBR1, DEGS1 | KEAP1 670/4885NFE2L2 12/4885MMP2 3228/4885 |
| US-20030130339-A1 | ALPHA, BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | QSOX1, CCNY, CBR1 | KEAP1 616/4885NFE2L2 18/4885MMP2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.